The decision concerns the time of filing and admissibility of a revocation action at the Central Division when a parallel infringement action is filed at a local division (Art. 33(4) UPCA). Art 33(4) UPCA states that...more
8/25/2023
/ Amgen ,
Amgen v Sanofi ,
Appeals ,
Dismissals ,
EU ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Luxembourg ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Revocation ,
Sanofi-Aventis
G1/23 – EPO Enlarged Board of Appeals of the EPO “available” (referral from T 0438/19) -
Under which circumstances can the public prior use of a product constitute prior art for novelty or inventive step[s], specifically...more
In this episode of our Exclusively Life Sciences webinar series, our experts from our EU team will share best practices for innovators to protect their competitive advantage when generics enter the market....more
When process patents are infringed, patent owners are often faced with considerable problems of providing proof of infringement. Effective enforcement is further impeded by the strict requirements set by German case law for...more